invoX Pharma to acquire F-star Therapeutics

23 June 2022
f-startx_large

invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical (HKEX: 1177) that is focused on research and development (R&D) and business development activities outside of China, today announced that it has entered into a definitive agreement to acquire all of the issued and outstanding shares of F-star Therapeutics’ (Nasdaq: FSTX) common stock for $7.12 per share.

The proposed acquisition values F-star, a UK and USA-based clinical-stage biopharmaceutical company,  at approximately $161 million. The transaction has been unanimously approved by the invoX and F-star boards of directors and is expected to close in the second half of 2022.

News of the M&A deal pushed F-star’s shares up a massive 69% to $3.98 in pre-market trading this morning.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology